Leveraging AI to Accelerate Drug Discovery: Vyasa Joins Certara
Applying Vyasa’s deep learning expertise to Certara products will enable our clients to expand how…
Certara2023 年 3 月 10 日
What you should know about FDA Project Optimus for your oncology drug approval
一直以来，肿瘤药物的剂量策略都以最大耐受剂量为重点。This…
Certara2023 年 3 月 10 日
RAPS Sponsored Webcast: Oops, I messed Up! How to Avoid (and Fix) Common Regulatory Submission Mistakes
糟了，申报出错啦！Everyone has made or seen one, and sometimes it is…
Certara2023 年 3 月 9 日
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel…
Certara2023 年 3 月 7 日
GlobalSubmit™ eCTD Platform
GlobalSubmit enables teams to simplify the eCTD submission process to successfully publish, validate, and review…
Certara2023 年 3 月 3 日
Drug Development Considerations for Live Biotherapeutic Products
A new class of complex biologics has emerged in recent years. These are classified in…
Certara2023 年 3 月 3 日
Advancing data discovery in the life sciences through artificial intelligence
Vyasa has developed deep-learning artificial intelligence solutions for organizations looking to solve the complex data…
Certara2023 年 3 月 2 日
Certara Announces Transition Plan For Chief Financial Officer
PRINCETON, N.J. – 2023 年 3 月 1 日 – Certara, Inc. （纳斯达克股票代码：CERT), announced today that John…
Certara2023 年 3 月 1 日
